143965-32-6

Basic information

• Product Name: (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone
• Synonyms: (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone;(4S)-3-(1-Oxohexyl)-4-(phenylMethyl)-2-oxazolidinone;(S)-4-Benzyl-3-hexanoyloxazolidin-2-one;(4S)-4-benzyl-3-hexanoyl-1,3-oxazolidin-2-one
• CAS NO: 143965-32-6
• Molecular Formula: C₁₆H₂₁NO₃
• Molecular Weight: 275.34284
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 143965-32-6.mol

Chemical Properties

• Boiling Point: 430.8±14.0 °C(Predicted)
• Appearance: /
• Density: 1.133±0.06 g/cm3(Predicted)
• Solubility: Chloroform, Methanol
• PKA: -2.31±0.40(Predicted)
• CAS DataBase Reference: (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone(143965-32-6)
• EPA Substance Registry System: (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone(143965-32-6)

Safety Data

• Hazardous Substances Data: 143965-32-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(S)-4-Benzyl-3-hexanoyl-2-oxazolidinone is used as an intermediate in the preparation of Prostaglandin derivatives. Prostaglandins are a group of naturally occurring lipid compounds that have various important functions in the body, such as regulating blood flow, inflammation, and pain. As an intermediate, (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone plays a crucial role in the synthesis of these biologically active compounds, contributing to the development of medications for various therapeutic applications.
Chemical Properties:
The chemical properties of (S)-4-Benzyl-3-hexanoyl-2-oxazolidinone include its colorless oil appearance, which suggests that it is a liquid at room temperature and does not have any visible color. This characteristic may be relevant for its use in the pharmaceutical industry, as it can be easily handled and processed in the synthesis of Prostaglandin derivatives.

Upstream product

• 90719-32-7 (S)-4-Benzyl-2-oxazolidinone 
• 142-61-0 Hexanoyl chloride 
• 2051-49-2 n-hexanoic anhydride 
• 109-72-8 n-butyllithium 
• 144-55-8 sodium hydrogencarbonate 
• 142-62-1 hexanoic acid 

Downstream Products

• 200866-59-7 tert-butyl (R)-3-((S)-4-benzyl-2-oxooxazolidine-3-carbonyl)heptanoate 
• 220805-28-7 4(S)-benzyl-3-[1-oxo-2(R)-(benzyloxymethyl)hexyl]-2-oxazolidinone 
• 235786-14-8 1-(4S-Benzyl-2-oxo-oxazolidin-3-yl)-2R-butyl-butane-1,3-dione 
• 189217-90-1 2(S)-(benzyloxymethyl)hexanol 
• 232926-00-0 2(R)-(benzyloxymethyl)hexyl iodide 
• 220805-33-4 2(R)-(benzyloxymethyl)hexanoic acid 
• 189218-03-9 5-benzyloxy-4(S)-n-butyl-2(R)-[2-(4-(4-fluorophenyl)phenyl)ethyl]pentanoic acid 
• 189218-00-6 L-prolinol 5-benzyloxy-4(S)-n-butyl-2(R)-[2-(4-(4-fluorophenyl)phenyl)ethyl]pentanamide 
• 189218-06-2 5-benzyloxy-4(S)-n-butyl-2(R)-[2-(4-(4-fluorophenyl)phenyl)ethyl]pentanoic acid 1-[(S)-tert-butylglycine methylamide] amide 
• 1217899-98-3 (4S,2'S)-4-benzyl-3-(2'-ethylhexanoyl)oxazolidin-2-one 
• 177607-70-4 (S)-4-benzyl-3-((S)-2-methylhexanoyl)oxazolidin-2-one 
• 1337552-69-8 C₄₂H₈₀O₅Si₃ 
• 1337552-79-0 C₄₂H₈₂O₅Si₃ 
• 1337552-81-4 C₃₆H₆₈O₅Si₂ 

Relevant articles and documents

Synthesis and Anticancer Activity of Novel Actinonin Derivatives as HsPDF Inhibitors

Human mitochondrial peptide deformylase (HsPDF) is responsible for removing the formyl group from N-terminal formylmethionines of newly synthesized mitochondrial proteins and plays important roles in maintaining mitochondria function. It is overexpressed

Synthesis and Absolute Configuration of Natural 2-Pyrones

2-Pyrones are frequently produced by microorganisms and often exhibit interesting bioactivities. Therefore, a short and easy synthetic access to these natural products is desirable. Synthetic routes to nectriapyrone, gibepyrone A, racemic gulypyrone A, (+)-germicidin C, (ent)-desoxygermicidin C and (ent)-prolipyrone A via a modular approach are presented, allowing the assignment of the absolute configurations of the latter three chiral compounds. The method failed for the synthesis of (ent)-phomapyrone B that was thus synthesized via a different route, resulting in an assignment of the absolute configuration of natural phomapyrone B.

Peptide deformylase inhibitors

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.

PEPTIDE DEFORMYLASE INHIBITORS

The present invention relates to a compound of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhi-bition of bacterial peptide deformylase (PDF) activity

A facile asymmetric synthesis of (S)-14-methyl-1-octadecene, the sex pheromone of the peach leafminer moth

An asymmetric synthesis of 14-methyl-1-octadecene, the sex pheromone of the peach leafminer moth has been achieved. The target molecule was synthesized in six linear steps and in 30.3% overall yield from commercially available hexanoyl chloride, (S)-4-benzyloxazolidin-2-one and 1,9-nonanediol. The hexanoyl chloride was connected with (S)-4-benzyloxazolidin-2-one, and with the induction of the chiral oxazolidinone auxiliary, after chiral methylation, LAH reduction and then tosylation gave the chiral key intermediate 5 in high stereoselectivity. 1,9-Nonanediol, was selectively brominated, THP protected and subjected to Li2CuCl4-mediated C-C coupling to afford a C12 intermediate. The target molecule, (S)-14-methyl-1-octadecene, was obtained after the two parts were subjected to a second Li 2CuCl4-mediated C-C coupling. Our synthetic approach represents the first time a substrate-control asymmetric synthesis of (S)-14-methyl-1-octadecene has been reported.

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS

The present invention is directed to novel compounds of formula (I) and their use in treating metabolic diseases.

The first enantioselective synthesis of cytotoxic marine natural product palau'imide and assignment of its C-20 stereochemistry

Methyl tetramate derivative 6 has been developed as a new building block for the flexible and racemization-free synthesis of methyl 5-benzyl-3- methyltetramate via alkylation, and used in the first asymmetric synthesis of palau'imide (1). This allowed the establishment of the hitherto unknown stereochemistry at the C-20 of palau'imide as S.

Peptide deformylase inhibitors of Mycobacterium tuberculosis: Synthesis, structural investigations, and biological results

Bacterial peptide deformylase (PDF) belongs to a subfamily of metalloproteases catalyzing the removal of the N-terminal formyl group from newly synthesized proteins. We report the synthesis and biological activity of highly potent inhibitors of Mycobacterium tuberculosis (Mtb) PDF enzyme as well as the first X-ray crystal structure of Mtb PDF. Structure-activity relationship and crystallographic data clarified the structural requirements for high enzyme potency and cell based potency. Activities against single and multi-drug-resistant Mtb strains are also reported.

Structure-activity relationships of the peptide deformylase inhibitor BB-3497: Modification of the methylene spacer and the P1′ side chain

Structural modifications to the peptide deformylase inhibitor BB-3497 are described. In this paper, we describe the initial SAR around this lead for modifications to the methylene spacer and the P1′ side chain. Enzyme inhibition and antibacterial activity data revealed that the optimum distance between the N-formyl hydroxylamine metal binding group and the P1′ side chain is one unsubstituted methylene unit. Additionally, lipophilic P1′ side chains that closely mimic the methionine residue in the substrate provided compounds with the best microbiological profile.

α-substituted hydroxamic acids as novel bacterial deformylase inhibitor-based antibacterial agents

We report the synthesis and biological activity of analogues of VRC3375 (N-hydroxy-3-R-butyl-3-[(2-S-(tert-butoxycarbonyl)-pyrrolidin-1-ylcarbonyl] propionamide), an orally active peptide deformylase inhibitor. This study explores the structure-activity relationship of various chelator groups, alpha substituents, P2′ and P3′ substituents in order to achieve optimal antibacterial activity with minimal toxicity liability.